UAE Animal Biotechnology Market By Product (Diagnostics, Biologics, Drugs, Reproductive And Genetic, Nutrition), By Application (Diagnosis of Animal Diseases, Treatment of Animal Diseases, Preventive Care of Animals, Product Research & Development, Others), By Animal Type (Companion, Livestock), By End Use (Laboratories, Point-of-care testing/In-house testing, Veterinary Hospitals & Clinics, Others), By Region, Competition, Forecast and Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 163.43 Million
CAGR (2026-2031)	7.96%
Fastest Growing Segment	Diagnosis of Animal Diseases
Largest Market	Abu Dhabi
Market Size (2031)	USD 258.77 Million

Market Overview

The UAE Animal Biotechnology Market will grow from USD 163.43 Million in 2025 to USD 258.77 Million by 2031 at a 7.96% CAGR. Animal biotechnology involves the application of scientific and engineering principles to modify living organisms within the animal sector, encompassing advanced diagnostics, vaccines, genetic improvements, and reproductive technologies. The market's expansion is fundamentally driven by the escalating demand for animal protein to address food security concerns, alongside concerted government efforts to enhance animal health and productivity through sustainable agricultural practices. According to the UAE Ministry of Climate Change and Environment, between January 1 and March 18, 2026, the UAE processed 1,454 livestock consignments, totaling 441,574 heads of diverse livestock, indicating significant activity in the animal sector that underpins biotechnology applications.

A notable impediment to market growth is the substantial initial investment required for research and development activities in animal biotechnology, coupled with the intricate regulatory pathways for product approval and commercialization. These factors can create high barriers to entry and innovation, potentially slowing the introduction of new biotechnological solutions within the UAE's animal industry.

Key Market Drivers

Government Support and Investment as a Catalyst for UAE Animal Biotechnology
Strong government support and strategic investments represent a primary catalyst for the UAE Animal Biotechnology Market. The government’s proactive approach, including fostering a conducive regulatory environment and providing direct financial backing, stimulates research, development, and commercialization of advanced animal health solutions. This commitment is evident in the tangible growth of the agricultural sector. According to the Abu Dhabi Registration Authority, as reported by Gulf News in December 2025, new licenses in the agriculture, fisheries, and livestock sector in Abu Dhabi increased by 29 percent in the first nine months of 2025, reaching 152. Such governmental encouragement provides a stable foundation, attracting both local and international players to invest in and innovate within animal biotechnology, particularly in areas like genetic improvements and vaccine development.

Rising Demand for Food Security and Premium Animal Protein
The increasing demand for food security and premium animal products further drives the market. As the UAE population expands and consumer preferences shift towards high-quality, safe, and sustainably sourced animal protein, there is a heightened reliance on biotechnology to enhance productivity, improve disease resistance, and ensure product safety. This is particularly crucial in meeting domestic consumption needs and reducing import dependency. For example, according to the United States Department of Agriculture in April 2025, chicken meat production in the UAE was projected to increase by 17 percent in 2025, reaching 70,000 metric tons. Furthermore, supporting this broader animal health ecosystem, there were approximately 1.5 million pet owners caring for more than 2 million animals across the UAE in November 2025, as reported by Pets in the City.

Download Free Sample Report

Key Market Challenges

Capital intensity and regulatory barriers impede market entry
The substantial initial investment required for research and development activities in animal biotechnology presents a significant impediment to market expansion. This financial barrier, often compounded by intricate regulatory pathways for product approval and commercialization, creates high entry hurdles. Consequently, smaller enterprises and startups are frequently deterred from entering the UAE animal biotechnology market, which limits the diversity of innovative solutions and potentially slows the pace of technological advancement within the sector. The capital-intensive nature of developing advanced diagnostics, vaccines, and genetic improvement technologies necessitates considerable upfront funding that few entities can readily commit.

Capital constraints hinder growth and infrastructure expansion
This financial burden directly hampers the growth of the UAE Animal Biotechnology Market by restricting competition and innovation. Securing the necessary capital for extensive laboratory work, clinical trials, and navigating complex approval processes consumes significant resources. For example, according to the U.S.-U.A.E. Business Council's January 2025 report, Masdar City Free Zone, a key hub for life sciences and biotechnology in the UAE, attracted foreign direct investment exceeding $272 million into its life sciences cluster, which includes numerous biotechnology and research facilities. Such figures underscore the substantial financial outlay necessary for establishing and operating advanced infrastructure, directly impeding the initiation and scaling of new biotechnology ventures essential for enhancing animal health and productivity in the region.

Key Market Trends

Genomic Technologies Drive UAE Animal Biotechnology and Conservation
Advancements in genomic selection and gene-editing technologies are profoundly shaping the UAE Animal Biotechnology Market by offering sophisticated tools for genetic improvement and biodiversity conservation. These technologies enable precise modifications to animal genomes, enhancing desirable traits in livestock such as disease resistance and productivity, which directly supports national food security objectives. Beyond agriculture, these advancements are critical for safeguarding endangered species, positioning the UAE as a leader in global conservation efforts. For instance, according to Dallas Innovates on February 3, 2026, in "Dallas-Based Colossal Gets $60M From U.A.E., Will Build a Modern 'Noah's Ark' in Dubai", the UAE invested $60 million directly into Colossal Biosciences for the establishment of the Colossal BioVault in Dubai, a global genetic repository aimed at preserving genetic material and generating genomic data.

Strategic Investment in Veterinary Biologics and Related Therapies
The increasing focus on biologics and advanced therapies in veterinary medicine represents another pivotal trend, expanding the scope of treatment options beyond traditional pharmaceuticals. This shift involves the development and application of vaccines, immunotherapies, and other biological products to prevent and treat animal diseases more effectively, leading to improved animal welfare and reduced economic losses for farmers. The adoption of these therapies is driven by a growing understanding of complex animal health issues and the desire for more targeted, efficacious solutions. This emphasis is supported by significant strategic initiatives, as, according to Healthcare World on June 11, 2025, in "UAE'S LIFE SCIENCES BOOM: DRIVING BIOTECH, PHARMA AND MEDICAL RESEARCH GROWTH IN THE UAE", the Ministry of Industry and Advanced Technology (MoIAT) allocated AED 300 billion over five years to key sectors, including pharmaceuticals and biotechnology.

Segmental Insights

Diagnosis of Animal Diseases: Fastest-Growing Segment
The key segmental insight for the UAE Animal Biotechnology Market highlights the Diagnosis of Animal Diseases as the fastest growing segment. This rapid expansion is primarily driven by an increased emphasis on animal health and welfare across both companion animals and livestock populations. Contributing factors include the rising prevalence of zoonotic diseases, necessitating robust surveillance and early detection capabilities. Furthermore, proactive regulatory measures by the Ministry of Climate Change and Environment (MOCCAE), alongside continuous investment in advanced diagnostic technologies, are enhancing the accuracy and accessibility of veterinary testing services, thereby reinforcing market growth and biosecurity standards across the nation.

Regional Insights

Abu Dhabi's Leadership in UAE Animal Biotechnology
Abu Dhabi leads the UAE Animal Biotechnology Market, primarily driven by significant governmental investment and strategic initiatives aimed at bolstering food security and enhancing animal health. The Abu Dhabi Agriculture and Food Safety Authority (ADAFSA) actively spearheads these advancements, including programs such as the Agricultural Genome Program. The emirate is home to pioneering institutions like the UAE BIOTECH Research Center, a recognized leader in animal cloning and genetic engineering, and Khalifa University's Center for Biotechnology, both contributing substantially to research and development. This focused commitment to advanced technologies and an evolving regulatory environment, now streamlined by the federal Emirates Drug Establishment (EDE), firmly establishes Abu Dhabi's dominant position within the market.

Recent Developments

• In November 2025, the UAE BIOTECH Research Center announced a significant breakthrough in conservation efforts by successfully cloning Arabian wolves, a species facing extinction. The two-month-old cloned wolves were exhibited to the public during the Al Ain International Hunting and Equestrian Exhibition. This pioneering research underscores the center's dedication to wildlife protection and the preservation of endangered species, complementing its ongoing work in safeguarding rare camel breeds. The initiative highlights the application of advanced animal biotechnology for ecological resilience within the UAE, showcasing the nation's scientific capabilities in genetic engineering for conservation.
• In June 2025, the Department of Health – Abu Dhabi and Sanofi formalized a strategic alliance aimed at accelerating the development of new global vaccines and bolstering regional manufacturing capabilities. The Memorandum of Understanding, signed at the BIO International Convention, leverages Abu Dhabi's health-tech ecosystem and advanced research infrastructure. This collaboration focuses on enhancing clinical research, optimizing resource allocation, and establishing funding frameworks for vaccine development. The partnership is a key step towards strengthening healthcare resilience and sustainability in Abu Dhabi and globally, particularly within the animal biotechnology context for vaccine innovation and production.
• In February 2025, Zoetis, in collaboration with its regional distributor Nova Pharma, introduced a new range of advanced therapeutic monoclonal antibodies to the UAE market. These innovative treatments, including Librela®, Solensia®, and Cytopoint®, were launched to address chronic conditions such as osteoarthritis and atopic dermatitis in companion animals. The introduction of these solutions represents a notable advancement in veterinary medicine within the UAE, providing veterinarians with targeted therapies to enhance the health and quality of life for pets. This product launch demonstrates the companies' commitment to advancing animal health through scientific innovation in the UAE's animal biotechnology sector.
• In August 2024, ADQ and E20 Investment Limited announced a collaboration to establish an innovative animal health platform in Abu Dhabi. This joint investment aims to expand the emirate's capacity for comprehensive veterinary healthcare and vaccine treatments. The strategic plan includes the development of state-of-the-art equine and camel hospitals. Furthermore, a new facility dedicated to advanced animal vaccine treatments is planned to serve the broader Middle East and Africa region. This initiative is designed to enhance the UAE's animal biotechnology infrastructure and capabilities in veterinary care and disease prevention.

Key Market Players

• Gulf Pharmaceutical Industries
• Neopharma LLC
• Dubai Biotechnology & Research Park
• Emirates Bio Farm
• Al Ain Farms for Livestock Production
• National Feed and Flour Production and Marketing Co. LLC
• United Veterinary Services LLC
• Al Rawabi Dairy Company
• IFFCO Group
• Pure Harvest Smart Farms

By Product	By Application	By Animal Type	By End Use	By Region
Diagnostics Biologics Drugs Reproductive And Genetic Nutrition	Diagnosis of Animal Diseases Treatment of Animal Diseases Preventive Care of Animals Product Research & Development Others	Companion Livestock	Laboratories Point-of-care testing/In-house testing Veterinary Hospitals & Clinics Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Animal Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Animal Biotechnology Market, By Product:

• Diagnostics
• Biologics
• Drugs
• Reproductive And Genetic
• Nutrition

• UAE Animal Biotechnology Market, By Application:

• Diagnosis of Animal Diseases
• Treatment of Animal Diseases
• Preventive Care of Animals
• Product Research & Development
• Others

• UAE Animal Biotechnology Market, By Animal Type:

• Companion
• Livestock

• UAE Animal Biotechnology Market, By End Use:

• Laboratories
• Point-of-care testing/In-house testing
• Veterinary Hospitals & Clinics
• Others

• UAE Animal Biotechnology Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE